January 2010 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study concluded that monthly pulse IV cyclophosphamide is effective for severe lupus nephritis in Indian patients, achieving complete or partial remission in 68.9% of cases, though longer follow-up is needed.
5 citations
,
August 1998 in “PubMed” In this case study, intravenous cyclophosphamide pulse therapy effectively improved symptoms of steroid-resistant lupus cystitis and peritonitis, allowing for a reduction in steroid dosage.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.
11 citations
,
July 2014 in “Clinical Rheumatology” This study found that Chinese female patients with systemic autoimmune diseases treated intravenously with cyclophosphamide were more likely to experience gastrointestinal discomfort, myelosuppression, and alopecia.
1 citations
,
June 2025 in “Asian Journal of Medical Sciences” In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.